N-Cur mitigates oxidative damage and inflammation, thereby preserving hepatic function during CDDP-based chemotherapy, and demonstrates significant potential as a hepatoprotective agent when administered concomitantly with CDDP chemotherapy.
Abstract
Objective: This research examined the effectiveness of liposomal N-Curcumin (N-Cur) against Cis-diamminedichloroplatinum (CDDP)-induced hepatotoxicity, specifically examining its ability to influence the Wnt/β-catenin/GSK-3 pathway and associated molecular markers. Methods: Male Wistar rats were treated for 14 days with oral N-Cur (80 mg/kg) and with a single intraperitoneal dose of CDDP (7 mg/kg) administered on day 7. Hepatic integrity was assessed through liver injury markers, histopathological examination, and biochemical analysis of oxidative stress (SOD, GSH, and MDA), inflammation (IL-10, TNF-α, CRP, and NF-κB p65), and signaling protein expression (β-catenin, Nrf2, and GSK-3). Results: CDDP administration resulted in significant hepatic damage, characterized by elevated injury markers and distorted tissue architecture. It induced severe oxidative stress (increased MDA; decreased GSH and SOD) and a robust inflammatory response. At the molecular level, CDDP suppressed the cytoprotective β-catenin and Nrf2 pathways while increasing GSK-3. Conversely, N-Cur treatment effectively reversed these pathological shifts by restoring antioxidant defenses, inhibiting pro-inflammatory mediators, and normalizing the Wnt/β-catenin/GSK-3 signaling axis. Conclusions: Liposomal N-Cur demonstrates significant potential as a hepatoprotective agent when administered concomitantly with CDDP chemotherapy. N-Cur mitigates oxidative damage and inflammation, thereby preserving hepatic function during CDDP-based chemotherapy. In addition, these favorable effects were associated with modulation of the Wnt/β-catenin/GSK-3 and Nrf2 pathways.
RUPA counteracts hepatotoxicity evoked by CISP in rats via its anti‐oxidative as well as anti‐inflammatory properties via repression of hepatic HMGB1/TLR4/NF‐κB and thus restricts the activation of NLRP3/caspase‐1 signaling cascade.
Shaimaa Mohamed Abdelrahman, A. Bekhit, Olivia N. Beshay· Journal of biochemical and m...· 0 citations
Abstract Cisplatin (CP), an effective chemotherapeutic agent, is known to cause cardiotoxicity, limiting its clinical application. This study aimed to investigate the potential cardioprotective effects of linagliptin (LG) against cisplatin-induced cardiac injury and to elucidate its underlying mechanisms. There were four groups of male Wistar rats: control, cisplatin (CP, 8 mg/kg, IP), and two groups with LG treatment (5 mg/kg and 10 mg/kg, orally) and CP. CP significantly increased cardiac injury markers (CK, CK-MB, TNNC1) and oxidative stress (decreased SOD and GSH, increased MDA) compared to controls (p < 0.05). It also elevated inflammatory cytokines (TNF-α, IL-6) and disrupted mitochondrial function (altered ATP level and NADP/NADPH ratios). Furthermore, CP decreased the expression of SIRT1 and Nrf2 and the level of p-AMPK. LG treatment dose-dependently attenuated these changes, with the 10 mg/kg dose showing greater efficacy. Histopathological examination and immunohistochemistry confirmed these biochemical findings, showing improved cardiac structure and increased expression of SIRT1 and Nrf2 with LG treatment. Linagliptin demonstrates potent cardioprotective effects against cisplatin-induced toxicity, primarily through modulation of the SIRT1/AMPK/Nrf2 signaling pathway, thereby resulting in reduced oxidative stress and inflammation. These findings suggest that linagliptin may serve as a potential adjuvant therapy to mitigate cisplatin-induced cardiotoxicity.
Mahdi H. Alsugoor, Naif Al Suhaymi, Bassim M S A Mohamed et al.· Drug and chemical toxicology...· 0 citations
Overall, nano-liposomal delivery enhanced the renoprotective efficacy of limonene, highlighting its potential as a therapeutic strategy against pesticide-induced kidney injury.
E. Elmorsy, Amina A. Farag, Amal M. Abdel-Kareim et al.· Toxics· 0 citations
Cyclophosphamide (Cyclo) is an effective chemotherapeutic agent, but its clinical use is limited by severe cardiotoxicity driven by oxidative stress, inflammation, and apoptosis. Natural antioxidants such as carnosic acid (CA) may offer protection. This study aimed to investigate the protective effects of CA against Cyclo-induced cardiotoxicity in rats and to elucidate the underlying molecular mechanisms. Forty male Wistar rats were divided into four groups: control, CA alone, Cyclo alone, and Cyclo + CA. CA was administered orally at 100 mg/kg for 14 days, while Cyclo was injected intraperitoneally at 100 mg/kg on day 14. Cardiac injury was assessed using serum biomarkers, histology, immunohistochemistry (NF-κB, TNF-α, IL-1β, caspase-3), RT-PCR (Keap-1, Nrf2, HO-1, Bax, Bcl-2), and oxidative stress markers. Cyclo significantly elevated serum cardiac injury markers (CK, troponin, and LDH), as well as hepatic injury markers (ALT and AST), and induced severe histopathological damage, including leukocytic infiltration, congestion, edema, and fibrosis. Mechanistically, Cyclo suppressed the Keap1/Nrf2/HO-1 pathway by downregulating Nrf2 and HO-1 while upregulating Keap-1. Cyclo also depleted antioxidant enzyme activities (SOD, GPx, CAT), increased lipid peroxidation (MDA), activated NF-κB-driven pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), and promoted apoptosis via upregulation of Bax and caspase-3 alongside downregulation of Bcl-2. Co-treatment with CA markedly reversed all these pathological changes, restoring antioxidant and Nrf2/HO-1 signaling, reducing inflammatory markers, inhibiting apoptosis, and improving cardiac histology. CA effectively attenuates Cyclo-induced cardiotoxicity through its antioxidant, anti-inflammatory, and anti-apoptotic properties. These protective effects are likely associated with modulation of the Keap-1/Nrf2/HO-1 and NF-κB signaling pathways, highlighting CA’s therapeutic potential as a natural cardioprotective agent in chemotherapy-associated cardiac injury. Proposed schematic representation of the cardioprotective mechanism of CA against Cyclo-induced cardiotoxicity based on the present findings and previously published literature. Cyclophosphamide exposure leads to cardiac damage through the induction of oxidative stress, inflammation (NF-κB-mediated), and disorganization of cardiac histology, ultimately resulting in cardiotoxicity. Carnosic Acid mitigates this damage by activating the KEAP-1/NRF2/HO-1 pathway. This activation inhibits cytosolic Nrf2 degradation, allowing it to translocate to the nucleus and activate the Antioxidant Response Element (ARE). Concurrently, CA inhibits the NF-κB cascade, reducing the expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). The combined effect is a reduction in oxidative stress (↓ROS, ↓MDA), inflammation, and apoptosis (as indicated by modulated Bax, Bcl-2, and Caspase-3), leading to decreased serum injury markers (CK, LDH, Troponin, AST, ALT, MDA), improved cardiac histology, and mitigation of cardiotoxicity.
Basma Salah, A. Abdelmonsef, Medhat Taha et al.· Bratislava Medical Journal· 0 citations
Arsenic trioxide (ATO) is a potent therapeutic agent against acute promyelocytic leukemia; nevertheless, its clinical utility is severely restricted by dose-limiting nephrotoxicity. This study investigated the protective potential of a radiation-synthesized gallotannin hydrogel (GTH) against ATO-induced kidney injury in rats. Forty male Wistar rats were randomized into four experimental groups: Control, ATO (4 mg/kg, i.p., for 4 weeks), GTH (2 mg/kg, i.p.), and ATO + GTH. GTH treatment was initiated during the third week of ATO administration, with GTH being administrated one hour prior to ATO injection. Following the experimental period, animals were sacrificed, tissue histology was examined, and renal function was assessed by serum urea and creatinine levels. Oxidative stress was evaluated via MDA, SOD, GSH, and GPx markers. Additionally, miR-223 and TXNIP expression levels were quantified using qRT-PCR. Inflammatory mediators (NF-κB, NLRP3, Caspase-1, IL-1β, and IL-18), endoplasmic reticulum (ER) stress markers (PERK, eIF2α, and CHOP), and the apoptotic marker caspase-3 were analyzed by ELISA. Our results revealed that GTH noticeably ameliorated kidney dysfunction, as evidenced by reduced serum urea and creatinine levels. Furthermore, GTH attenuated oxidative stress by decreasing MDA levels and restoring antioxidant enzyme activities (SOD, GSH, and GPx). Histological analysis confirmed that GTH mitigated structural renal damage. Molecularly, GTH administration suppressed the ATO-induced upregulation of miR-223 and TXNIP. This downregulation correlated with a reduction in inflammatory mediators, attenuation of ER stress markers, and decreased apoptosis. These findings demonstrate that radiation-synthesized gallotannin hydrogel (GTH) exerts nephroprotective effects against ATO-induced nephrotoxicity. These benefits are driven by antioxidant, anti-inflammatory, and anti-apoptotic mechanisms mediated via modulation of the miR-223/TXNIP axis.
Omayma A. R. Abo-Zaid, Mostafa A. Farrag, Aya S. R. Shaaban et al.· Biological Trace Element Res...· 0 citations
The protective mechanism involves anti-oxidant enhancement and inhibition of oxidative stress-induced inflammation and apoptosis, supporting the therapeutic potential of HSP in managing phthalate-related renal injury.
Tuba Karaarslan, B. Yıldırım, F. Yildirim et al.· Iranian Journal of Basic Med...· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
